Systasy Bioscience uses human cellular disease models, synthetic biology engineering, and artificial intelligence to unlock drug discovery for genetically complex disorders.
Systasy’s Barcoded Drug Discovery Engine engages the multi-modal deep phenotyping approach together with large-scale data analytics to access the black box of disease-relevant cell signaling networks.
Attempts to discover new drugs for genetically complex brain disorders have proven extremely difficult. Insufficient knowledge of the underlying biological mechanisms represents a critical challenge impacting the drug discovery process. This challenge is driving the need for innovative high-throughput screening methods boosted by artificial intelligence-powered analyses that can elucidate the complex cellular communication, such as in primary mouse neurons and human disease models, in the early stages of drug discovery.
At Systasy, we address this need by delivering unmatched mode-of-action insights through highly multiplexed phenogenomic pathway profiling technologies for target selection, lead discovery, and selectivity profiling.